FDA approves Onswik as once-weekly basal insulin for adults with type 2 diabetes
The FDA has approved Lilly's Onswik as a once-weekly basal insulin for adults with type 2 diabetes, reducing the frequency of basal insulin injections from daily to weekly dosing.
Onswik, or insulin efsitora alfa-gobe, was supported by the Phase III QWINT clinical programme involving more than 3,400 adults with type 2 diabetes.
The approval introduces a weekly basal-insulin option that could simplify treatment schedules for adults who require insulin therapy.
Field | Content |
Alert Type | Approval |
Drug Name | Insulin efsitora alfa-gobe |
Brand Name | Onswik |
Company | Eli Lilly and Company |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | New drug approval |
Indication | Adults with type 2 diabetes requiring basal insulin treatment |
Therapy Area(s) | Diabetes; endocrinology; metabolic disease |
Technology or Modality | Once-weekly basal insulin |
Dosing | Once weekly |
Clinical Programme | Phase III QWINT programme |
Clinical Programme Population | More than 3,400 adults |
Geography | United States |
What Happened | The FDA approved Onswik as a once-weekly basal insulin treatment for adults with type 2 diabetes. |
Why It Matters | Weekly administration substantially reduces injection frequency compared with conventional once-daily basal insulin schedules. |
Supporting Context | Lilly estimates that once-weekly administration can reduce basal insulin injections from approximately 365 to 52 per year. |
Potential Impact | A simplified injection schedule could reduce treatment burden and improve convenience for adults requiring long-term basal insulin therapy. |
Key Takeaway | Onswik introduces once-weekly basal insulin dosing for adults with type 2 diabetes in the United States. |
What to Watch | Commercial launch, payer coverage, prescribing uptake and real-world treatment adherence. |
Primary Source | Eli Lilly and Company |
Relevant Date | 24 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários